Merz established its North America division in Greensboro in 1995 and kept it there until January 2015, when it consolidated operations at its 60,000-square-foot facility in Raleigh.
If you are seeking funding for your technology, please contact one of our representatives through the contact form below.Please note that if you submit information to Merz all materials submitted by electronic or physical communication will be deemed non-confidential. Do not submit any information or other materials that you consider to be confidential or proprietary.
Disclamer Merz’s R&D programs are fully aligned with our global focus on aesthetics and neurotoxins, both of which represent emerging fields with considerable growth potential. Through the Merz Corporate Venture Capital Initiative, we offer up initial funding in the early stages of development of a company or technology and are committed to further investments in pace with the company’s progress. Cytrellis’ key proprietary technology removes excess skin without invasive surgery or scarring. A broad and well-coordinated portfolio of minimally invasive and non-invasive skin rejuvenation measures ensures that the needs and wishes of each patient can be individually addressed during treatment.Learn more about the non-surgical lift that's making beautiful changes arround the world.For patients with movement disorders, botulinum neurotoxin is often the treatment of choice. Since then, tetesept offers a large selection of high-quality and at the same time innovative health products.
A detailed picture of the Casimersen in Seven Major Markets, i.e., United States, EU5 (German...Overview
The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. We invest globally in companies who are pursuing innovative, breakthrough science. More than 300 Merz employees worldwide focus on innovation and R&D activities, and approximately 100 million euros per year are dedicated to the development of additional products, new formulations and novel indications. It’s there that Merz Aesthetics will become the largest dedicated medical aesthetics business globally. Tinnitus - 2018 Pipeline Insights featuring Knopp Biosciences, Auris Medical, Palau Pharma, Otonomy, Merz Pharma, and more - ResearchAndMarkets.com September 07, … With our relentless research, development, and culture of innovation, we strive to serve unmet patient needs and realize better outcomes.
Since creating one of the first anti-wrinkle moisturizing creams in 1953, Merz has been a driver of innovation in the field of aesthetic medicine. 2 Teijin Receives Marketing Approval for Merz’s Xeomin Frankfurt am Main, Germany / July 1, 2020 Merz Pharmaceuticals GmbH, a leading neurotoxin company and subsidiary of Merz Pharma GmbH & Co. KGaA, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, jointly…
If you would like to submit a speculative application or apply for an open position, please make sure Please note that we cannot consider your application if you send it via any other channel. PIPELINE HIGHLIGHTS Atrial Fibrillation is one of the widely researched conditions during 2020 with 23 companies actively focusing on realizing pipeline's potential. Merz’s R&D programs are fully aligned with our global focus on aesthetics and neurotoxins, both of which represent emerging fields with considerable growth potential.Over the past five years, Merz has successfully completed numerous acquisitions in the medical aesthetics space, bringing in technologies and talent to create a comprehensive aesthetics portfolio of toxins, fillers, energy-based devices and skincare. Merz Pharma GmbH & Co. KGaA is a privately-held pharmaceutical company based in Frankfurt, Germany with affiliates across Europe, as well as the US, Canada, Mexico, Brazil and Asia Pacific and regional headquarters in Singapore and North Carolina, USA. This could be alone, or in conjunction with other venture capital and investment funds.We are seeking outstanding ideas and promising technologies that are capable of generating a high level of consumer interest.Although our interest is primarily focused on early stage projects and seed investments, our goal is to maximize the value of our entire portfolio, including the development of promising later stage investments and opportunities across all of Merz’s focus areasWe pride ourselves on our long-standing commitment to both innovation and continuity.